Online inquiry

IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ357MR)

This product GTTS-WQ357MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ALB&IL6R gene. The antibody can be applied in Inflammatory conditions, Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000477.7; NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 213; 3570
UniProt ID P02768; P08887
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ357MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ209MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ10806MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ12323MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ6671MR IVTScrip™ mRNA-Anti-MUC16, DMUC5754A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DMUC5754A
GTTS-WQ15213MR IVTScrip™ mRNA-Anti-TNFSF13&TNFSF13B, TACI-Fc(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA TACI-Fc
GTTS-WQ4311MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ11235MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI3902
GTTS-WQ3703MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 2287409
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW